Clinical Trial Update: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

View source ↗

Summary

Expanded Access study of TAS-120 (futibatinib) in patients with advanced cholangiocarcinoma harboring FGFR2 rearrangements, with the drug reported as approved f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• TAS-120 (futibatinib)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Advanced Cholangiocarcinoma | Status: APPROVED_FOR_MARKETING